Big pharma often extends product monopolies through secondary patents, covering delivery mechanisms, isomers, dosage regimens, or combinations
Instead, it identifies predispositions that may inform why certain GLP-1 formulations or dual-peptide approaches (like GLP-Squared, which combines GLP-1 and GIP signaling) might be more aligned with your metabolic profile
Li H 2017 Pentadecapeptide bpc 157 attenuates lipopolysaccharide--induced acute lung injury via inhibition of nuclear factor kappa b activation Exp Ther Med 14(6): 56075612 Sun Y
2 (Ozempic, Rybelsus) SUSTAIN: HbA1c 1,5-1,8%, SUSTAIN-6: 26% MACE
Although Tesomet received an Orphan Drug designation from the FDA in 2021, its development was discontinued in 2022 due to funding constraints